(Q27852864)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Regorafenib in metastatic colorectal cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

Andrea Sartore-Bianchi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

A Amatu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Salvatore Siena

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Annalisa Zeppellini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Riccardo Ricotta

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Katia Bencardino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

publication date

1 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Anticancer Therapy

8 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

255-265

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Evolving treatment of advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Targeting RET for thyroid cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

21 January 2018

KIT mutations in GIST.

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.2014.894887

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1038/NATURE11156

Identifiers

DOI

10.1586/14737140.2014.894887

2 references

13 November 2016

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24559322%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

2 references

13 November 2016